AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06246266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Helfer Skin Tap Technique group
Description: During intramuscular vaccine administration, the muscle will be tapped with the palmar surface of the fingers of the other hand that is not used, with light rhythmic movements, counting for 1-15 seconds. Then, when the muscle is entered with the injection, it will continue to be hit with light rhythmic movements for 1-3 seconds. Thus, the muscle will relax and the fibers around the muscle will be stimulated. Mechanical stimulation given with the Helfer Skin Tap technique during intramuscular vaccine administration will distract the baby's attention.
Study NCT06246266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ShotBlocker Technique group
Description: The protruding but not sharp surface on the ShotBlocker tool will be placed on the baby's skin before intramuscular vaccine administration.~Injection will be applied to the middle part of this vehicle, which has a 'U' appearance. This tool, which does not cause any harm to the skin surface, will provide stimulation to the muscle fibers according to the Gate Control Theory related to pain.
Study NCT05163782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New ankle foot orthosis with anterior support
Description: New ankle foot orthosis with anterior support developed by Turbomed
Study NCT04714619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: Patients will receive CB-103 capsules orally (QD) in combination with NSAI therapy (letrozole or anastrozole, continuing prior therapy) also orally once daily, and based on a 28-day treatment cycle.~A run-in phase for safety and tolerability of CB-103 in combination with anastrozole or letrozole will be conducted as an initial step of the phase II trial to confirm the safe dose of CB-103 in combination with NSAI given at standard dose.~Patients will receive treatment until disease progression (as defined by RECIST v.1.1), symptomatic deterioration, unacceptable toxicity, death, consent withdrawal or study termination, whichever occurs first.
Study NCT05625256 — intervention group
Intervention type: DEVICE
Intervention: SentiCor-300
Description: Continuous blood pressure measurement with the SentiCor-300.
Study NCT05242029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Participants will receive 40mg psilocybin in a clinical setting.
Study NCT05242029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Participants will receive 40mg psilocybin in a clinical setting.
Study NCT05163782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis with anterior support
Description: Ankle foot orthosis with anterior support from Turbomed
Study NCT05163782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis from competitor 1
Description: Ankle foot orthosis with posterior support from competitor 1
Study NCT05163782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis from competitor 2
Description: Ankle foot orthosis with posterior support from competitor 2
Study NCT04663724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Based Treatment
Description: A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
Study NCT04663724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-Based Treatment
Description: A 4-week (8 30-minute sessions) course of computer-based treatment involving viewing pictures of faces while music may play. Participants will receive research treatment twice a week.
Study NCT05808881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene Hydrochloride Injection
Description: for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
Study NCT05808881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone Hydrochloride Injection
Description: for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
Study NCT06019741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban and aspirin 80
Description: rivaroxaban 2.5 mg twice daily orally added to aspirin 80 mg post coronary bypass surgery
Study NCT06019741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 80
Description: aspirin 80 mg orally post coronary bypass surgery
Study NCT04772482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sensitivity Patch Testing
Description: Testing patches will be applied on the upper arms. Para-phenylene diamine (PPD) 1% will be applied on one upper arm. Para-toluenediamine sulfate (PTD), 2-methoxyethyl p-phenylenediamine (ME-PPD), PPD6 and PPD7 will be applied to the other upper arm.
Study NCT06474728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus
Description: Treatment with an Emollient Containing Postbiotic Saccharomyces and Lactobacillus, with the dose of 100g per week,lasting for 12weeks.
Study NCT05737914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic thoracic T3 sympathectomy
Description: Interruption of intrathoracic sympathetic neural pathway surgically to treat hyperhidrosis by using video - thoracoscopy
Study NCT05737914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ThoracicT3 radiofrequency ablation
Description: radiofrequency ablation at third thoracic spine it may be a good option for treatment of primary hyperhidrosis.
Study NCT04665271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zemedy App
Description: Digital smart phone app that delivers cognitive-behavioral therapy for IBS
Study NCT04665271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zemedy App
Description: Digital smart phone app that delivers cognitive-behavioral therapy for IBS
Study NCT06436196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: Use of Video laryngoscope to secure airway
Study NCT06436196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: Macintosh or Miller's laryngoscopes used to secure paediatric airways
Study NCT05147051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine Sodium Succinate
Description: 500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute
Study NCT05147051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute
Study NCT04474938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16mg/kg, QW Cycles 1-2 (28 days/cycle), Q2W Cycles 3-6, and Q4W thereafter for up to 1 year
Study NCT04474938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.3mg/m2 of subcutaneous bortezomib on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
Study NCT04474938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg of dexamethasone on days 1, 8, 15 and 22 of a 28-day cycle for 6 cycles
Study NCT06195943 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Intervention with use of El-Fit App
Description: Along with wearing their Fitbit daily, subjects will be asked to use El-Fit app to participant in daily exercise as much or a little as they want over the course of the study.
Study NCT00817973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Casein
Study NCT00817973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey
Study NCT00817973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cod
Study NCT00817973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Study NCT06106529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin 5 mg twice per day for 6 weeks
Study NCT06106529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
Study NCT06014840 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Description: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Study NCT04948853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement Support - Supported Employment
Description: Individual, person-centered intervention designed to help individuals living with mental illnesses obtain and sustain meaningful employment. This is an evidence-based practice for individuals with severe mental illnesses.
Study NCT06014840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Description: Assessment and Treatment provided to participant by a respirologist using evidence-based guidelines for asthma or COPD
Study NCT06301425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Patients in interventional group could choose one of the following treatment protocols and then receive allo-HSCT if they were CR after the second consolidation:~1. . Venetoclax plus azacitidine: azacitidine 75mg/m2/d d1-7; venetoclax 400mg/d, d1-21;~2. . Venetoclax plus CAG: venetoclax 400mg qd d1-14; aclacinomycin 20mg qd d1-4; cytarabine 10mg/m2 q12h subcutaneous injection d1-14; G-CSF 300μg qd d1-14;~3. . Venetoclax plus IA: venetoclax 400mg qd d1-4; idarubicin 10mg qd d1-4; cytarabine 500mg qd d1-4;~4. . Venetoclax plus AA: venetoclax 400mg qd d1-7; aclacinomycin 20mg qd d1-7; cytarabine 100mg/m2 qd d1-7.
Study NCT06301425 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Receive allo-HSCT directly without the second consolidation chemotherapy.
Study NCT04802811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 1 or Placebo-dose 1
Study NCT04802811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 2 or Placebo-dose 2
Study NCT04802811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 3 or Placebo-dose 3
Study NCT04802811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 4 or Placebo-dose 4
Study NCT04802811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2150；Placebo
Description: Single dose；SHR2150-dose 5 or Placebo-dose 5
Study NCT05927038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Description: After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of caffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
Study NCT05927038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Description: After 2 weeks of coffee abstinence (washout), participants who were coffee drinkers were randomly allocated to receive either 4 sachets (1.8g each) of decaffeinated instant coffee per day for 3 weeks. Participants were blinded to coffee contents.
Study NCT04891016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT combined with toripalimab
Description: Patients received FLOT combined with toripalimab on Day 3 every 3 weeks, for a total of 3 cycles, followed by surgical treatment. Postoperative adjuvant therapy was determined based on pathological results: if a pathological complete response (pCR) was achieved, patients received 2 additional cycles of the neoadjuvant regimen; if pCR was not achieved, patients were given 4 cycles of SOX combined with toripalimab postoperatively.
Study NCT04914780 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Education intervention with mobile application for 4 weeks
Study NCT05999695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management
Description: The experimental group received the SelfManagement Program for Acute Coronary Syndrome:~the research subjects completed the first data collection within one week of hospitalization. Guide the research subjects to browse this manual and watch the Acute Coronary Self-Care Video, and explain what they do not understand, hoping to stimulate the research subjects to discuss nursing issues, and jointly formulate self-management goals, and This handbook was given to study subjects to take home. Telephone interviews every 2 weeks in the first month after discharge, and then again after two and three months after discharge. Each call is about 10 minutes to track the completion of goals and self-management,including usual medication, regular exercise, balance Food and spiritual support and encouragement, etc.,and clarify any doubts.
Study NCT05999695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular care
Description: gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text.
Study NCT05441826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB119
Description: Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.
Study NCT05999695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular care
Description: gular care regular care The nurse implements routine nursing instructions, including disease and treatment profiles,symptom management, and outpatient follow-up. Scan the QRC with your mobile phone or provide the Care Guidance Leaflet for Coronary Artery Disease and Caring for Myocardial Infarction Patients which are all written in text.
Study NCT06440473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast 0.3% cream
Study NCT06440473 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Roflumilast 0.3% vehicle cream)
Description: Vehicle (Roflumilast 0.3% vehicle cream)
Study NCT05720650 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06021314 — intervention group
Intervention type: OTHER
Intervention: Brace
Description: Cheneau type scoliosis brace due to brace indication for adolecant idiopatic scoliosis
Study NCT05624476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mNGS of urine cell-free DNA
Description: Metagenomic sequencing of urine cell-free DNA
Study NCT04758702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-PRF (Leucocyte- platelet rich fibrin)
Description: Leucocyte-Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly. Patient's own blood is centrifuged using (Intra-spin) FDA approved centrifuge on 45 degrees angle on 2700 rpm for 12 minutes.
Study NCT04758702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H-PRF (Horizontal -platelet rich fibrin)
Description: Platelet rich fibrin is a high density fibrin clot. it serves as a biological healing matrix by supporting cell migration and cytokine release, expanding the range of its potential applications greatly.Horizontally centrifuged platelet rich fibrin using (Bio-prf) centrifuge on 700 g force for 8 minutes. On a horizontal centrifugation, the cells separate much more efficiently throughout the entire membrane. This leads to better layer separation and also favors cells that are evenly distributed throughout the PRF clot.
Study NCT04758702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical stent
Description: An essix surgical stent will be obtained using a high vacuum suction and used to protect the denuded donor site after suturing the wound. (Biostar® Scan/Biostar®V) will be used to make the stent.
Study NCT04026880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: 25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
Study NCT04026880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by intramuscular injection weekly for 12 weeks
Study NCT06201260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermittent pneumatic compression protocol
Description: A 30 min IPC protocol at about 200mmHg
Study NCT06201260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The electrodes of an electrostimulation device (SP 4.0, Compex, Guildford, United Kingdom) will be positioned on participants' quadriceps. Participants will be informed that they are engaging an innovative microcurrent treatment. This procedure will last for 30 min.
Study NCT05189873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long GnRH agonist + HRT
Description: Intervention group:(Long GnRH agonist + HRT) From day 18-21 of the previous cycle, 0.5 cc of Superfect is injected daily and vaginal ultrasound is performed 10-14 days later If the endometrial thickness is less than 5 mm and there are no ovarian cysts, estradiol is started like HRT treatment and the agonist dose of GnRH starts with estradiol. It is halved (0.25 cc superfect) and superfect is prescribed until progesterone is started. At the time of progesterone administration, the administration of superfect is discontinued. Injections of estradiol and progesterone is the same as for the HRT group
Study NCT05189873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRT
Description: In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
Study NCT05479201 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Home based sleep test
Description: Home based sleep test to calculate apnea hypopnea index (AHI) for evaluation of sleep apnea, sleep quality (SQI) and sleep duration (SD)
Study NCT06335602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER acupuncture
Description: Low level LASER therapy
Study NCT06335602 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LASER acupuncture
Description: Low level LASER therapy
Study NCT06335602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER acupuncture
Description: Low level LASER therapy
Study NCT04246151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Vancomycin capsules
Study NCT05661786 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Monitor every 6 months
Study NCT05661786 — intervention group
Intervention type: OTHER
Intervention: Antiviral treatment
Description: Receive first-line antiviral treatment, including entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide, tenofovir amibufenamide or peginterferon
Study NCT05631561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular denervation System (Generator and Catheter )
Description: All patients receive endovascular denervation (EDN) treatment
Study NCT05004831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib plus TAS-102
Description: fruquintinib 4mg/d, qd po, D1-21, Q4W; TAS-102 70mg/m2/d, bid po, D1-5, 8-12, Q4W
Study NCT04897217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol Acetate
Description: The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
Study NCT04897217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel Drug Implant
Description: Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.
Study NCT04750291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 1 infiltration in the biceps muscle with botulinum toxin (100 IU)
Study NCT04750291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 infiltration in the biceps muscle with placebo or sterile saline
Study NCT04246151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Culturelle
Description: Culturelle capsules